22. There are approximately 1,000–1,650 new cases diagnosed annually in the U.S. 11-13

• Although they do not metastasize, desmoid tumors are associated with:
  - life threatening. 3,8
  - age and are 2–3 times more likely to be diagnosed in women than men. 9,11
  - These tumors are difficult to control and can be debilitating for people with:
    - severe pain, loss of physical function and impact a person’s quality of life. 2–7
  - These tumors lead to:
    - “disease limbo”, at best. 2
• There are no standard treatments for desmoid tumors.

19. OGSIVEO has been evaluated in a Phase 3 clinical trial in refractory desmoid tumors.

18. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

17. The most common laboratory abnormalities (

16. Decreased phosphate (65%) and potassium (22%) occurred in OGSIVEO-treated patients. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose routinely during treatment.

15. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

14. The overall response rate (ORR) was 21% with OGSIVEO versus 8% with placebo (p<0.001); the complete response rate was 8% in the OGSIVEO arm and 0% in the placebo arm. The trial results were published in the March 9, 2023 issue of the New England Journal of Medicine.

13. The trial enrolled over 300 patients with refractory desmoid tumors from 47 sites in the U.S., including a broad range of tumor locations and a variety of prior treatments, with over 90% of patients having undergone prior systemic treatment.

12. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

11. The overall response rate (ORR) was 21% with OGSIVEO versus 8% with placebo (p<0.001); the complete response rate was 8% in the OGSIVEO arm and 0% in the placebo arm. The trial results were published in the March 9, 2023 issue of the New England Journal of Medicine.

10. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

9. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

8. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

7. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

6. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

5. OGSIVEO achieved statistically significant and clinically meaningful improvements in:

REFERENCES


• Prescribing Information. SpringWorks Therapeutics, Inc. OGSIVEO. 2023 Mar 9;388(10):898-912.


• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea:

• The most common laboratory abnormalities were:

• Electrolyte Abnormalities:

• Ovarian Toxicity:

• Diarrhea: